VCs Think Twice About Type 2 Diabetes Investments
Executive Summary
Venture capitalists are reevaluating type 2 diabetes investments in light of daunting new regulatory hurdles and an economic climate that limits their ability to cash out of such companies in a timely fashion. But, say some VCs, truly innovative compounds may be worth the bigger R&D bills and longer time to exit given the dazzlingly large market at stake
You may also be interested in...
FDA's Throckmorton Says There Is No "Systematic Conservatism" On Diabetes Drugs
Based on the number of investigational new drug applications submitted and meetings requested with FDA, the agency's requirements for studying the cardiovascular safety of diabetes drugs have not had a dramatically negative effect on innovation, despite “allegations” to the contrary, asserted the agency’s deputy director Douglas Throckmorton at the American Diabetes Association meeting.
FDA's Throckmorton Says There Is No "Systematic Conservatism" On Diabetes Drugs
Based on the number of investigational new drug applications submitted and meetings requested with FDA, the agency's requirements for studying the cardiovascular safety of diabetes drugs have not had a dramatically negative effect on innovation, despite “allegations” to the contrary, asserted the agency’s deputy director Douglas Throckmorton at the American Diabetes Association meeting.
FDA's Throckmorton Says There Is No "Systematic Conservatism" On Diabetes Drugs
Agency data show no evidence for charges that cardiovascular guidance killed drug development, official says at ADA meeting.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: